GDC-0879

• CAT Number: I005410
• CAS Number: 905281-76-7
• Molecular Formula: C19H18N4O2
• Molecular Weight: 334.37
• Purity: ≥95%
• Synonyms: 2-[4-[(1E)-1-hydroxyimino-2,3-dihydroinden-5-yl]-3-pyridin-4-ylpyrazol-1-yl]ethanol
• Target: Raf
• Solubility: DMSO ≥64mg/mL Water <1.2mg/mL Ethanol ≥4.8mg/mL
• Storage: 3 years -20C powder
• IC50: 0.13 nM [1]
• InChI: InChI=1S/C19H18N4O2/c24-10-9-23-12-17(19(21-23)13-5-7-20-8-6-13)15-1-3-16-14(11-15)2-4-18(16)22-25/h1,3,5-8,11-12,24-25H,2,4,9-10H2/b22-18+
• InChIKey: DEZZLWQELQORIU-RELWKKBWSA-N
• SMILES: C1C/C(=N\O)/C2=C1C=C(C=C2)C3=CN(N=C3C4=CC=NC=C4)CCO

GDC-0879 (CAT: I005410) is a novel, potent, and selective inhibitor of B-Raf kinase, specifically targeting the mutant B-Raf V600E. This mutation is a critical driver in various cancers, including melanoma and colorectal cancer. By inhibiting B-Raf activity, GDC-0879 effectively suppresses the MAPK/ERK signaling pathway, leading to decreased cell proliferation and increased apoptosis in tumor cells. Its high specificity and efficacy make it an invaluable tool for studying oncogenic B-Raf signaling, resistance mechanisms, and therapeutic strategies in cancer research. GDC-0879 is a key compound for advancing targeted therapies in oncology.